Paper35637402
Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors.
Zhang H and 26 others. Nat Cancer, 2022. Cited by 49 papers, by iCite.
Cite this record
ConductScience Library. Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors. Papers, record 35637402. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35637402
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoplasms | Major topic |
| Poly(ADP-ribose) Polymerases | Major topic |
| Receptors, Chimeric Antigen | Major topic |
| Humans | |
| Immunosuppression Therapy | |
| Immunotherapy, Adoptive | |
| Tumor Microenvironment |
Source PubMed
Grants8
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 HD103027 | NICHD NIH HHS | United States | R01HD103027 | PubMed | NIH RePORTER |
| P01 CA165997 | NCI NIH HHS | United States | P01CA165997 | PubMed | NIH RePORTER |
| R56 AG069745 | NIA NIH HHS | United States | R56AG069745 | PubMed | NIH RePORTER |
| R01 CA233790 | NCI NIH HHS | United States | R01CA233790 | PubMed | NIH RePORTER |
| R01 CA247803 | NCI NIH HHS | United States | R01CA247803 | PubMed | NIH RePORTER |
| R01 CA240814 | NCI NIH HHS | United States | R01CA240814 | PubMed | NIH RePORTER |
| R15 HD100970 | NICHD NIH HHS | United States | R15HD100970 | PubMed | NIH RePORTER |
| K08 CA252619 | NCI NIH HHS | United States | K08CA252619 | PubMed | NIH RePORTER |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 35883000 | PARP11 interfer(on)es with CAR T cell efficacy. | https://conductscience.org/library/papers/35883000 |
Source PubMed
References50
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33750922 | Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. | Nat Rev Cancer | 2021 | https://conductscience.org/library/papers/33750922 | PubMed |
| 2 | 30523282 | Cancer immunoediting and resistance to T cell-based immunotherapy. | Nat Rev Clin Oncol | 2019 | https://conductscience.org/library/papers/30523282 | PubMed |
| 3 | 17476343 | Immune surveillance of tumors. | J Clin Invest | 2007 | https://conductscience.org/library/papers/17476343 | PubMed |
| 4 | 22439926 | Accessories to the crime: functions of cells recruited to the tumor microenvironment. | Cancer Cell | 2012 | https://conductscience.org/library/papers/22439926 | PubMed |
| 5 | 25838376 | T cell exclusion, immune privilege, and the tumor microenvironment. | Science | 2015 | https://conductscience.org/library/papers/25838376 | PubMed |
| 6 | 26787424 | Targeting regulatory T cells in tumors. | FEBS J | 2016 | https://conductscience.org/library/papers/26787424 | PubMed |
| 7 | 28192720 | Dendritic cells in cancer: the role revisited. | Curr Opin Immunol | 2017 | https://conductscience.org/library/papers/28192720 | PubMed |
| 8 | 29059149 | Targeting immunosuppressive adenosine in cancer. | Nat Rev Cancer | 2017 | https://conductscience.org/library/papers/29059149 | PubMed |
| 9 | 32514148 | The adenosine pathway in immuno-oncology. | Nat Rev Clin Oncol | 2020 | https://conductscience.org/library/papers/32514148 | PubMed |
| 10 | 26598942 | Combination cancer immunotherapies tailored to the tumour microenvironment. | Nat Rev Clin Oncol | 2016 | https://conductscience.org/library/papers/26598942 | PubMed |
| 11 | 25860605 | Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. | Cell | 2015 | https://conductscience.org/library/papers/25860605 | PubMed |
| 12 | 23570388 | Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy. | J Interferon Cytokine Res | 2013 | https://conductscience.org/library/papers/23570388 | PubMed |
| 13 | 26911188 | Antitumour actions of interferons: implications for cancer therapy. | Nat Rev Cancer | 2016 | https://conductscience.org/library/papers/26911188 | PubMed |
| 14 | 26027717 | Type I interferons in anticancer immunity. | Nat Rev Immunol | 2015 | https://conductscience.org/library/papers/26027717 | PubMed |
| 15 | 27912061 | Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. | Cell | 2016 | https://conductscience.org/library/papers/27912061 | PubMed |
| 16 | 16585541 | CD8 T cells specific for lymphocytic choriomeningitis virus require type I IFN receptor for clonal expansion. | J Immunol | 2006 | https://conductscience.org/library/papers/16585541 | PubMed |
| 17 | 15814665 | Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. | J Immunol | 2005 | https://conductscience.org/library/papers/15814665 | PubMed |
| 18 | 21108462 | Effects of IFN-α as a signal-3 cytokine on human naïve and antigen-experienced CD8(+) T cells. | Eur J Immunol | 2010 | https://conductscience.org/library/papers/21108462 | PubMed |
| 19 | 28196594 | Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. | Cancer Cell | 2017 | https://conductscience.org/library/papers/28196594 | PubMed |
| 20 | 23045272 | Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses. | Oncogene | 2013 | https://conductscience.org/library/papers/23045272 | PubMed |
Cited by34
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 49 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42981393 | IFNAR1 stabilization sustains CD8+ T cell persistence in IFN-high colorectal cancer liver metastases. | Sci Adv | 2026 | https://conductscience.org/library/papers/42981393 | PubMed |
| 42760581 | Co-stimulatory signal deficiency impairs cytotoxic T lymphocyte function in tumor immune evasion: molecular mechanisms and therapeutic implications. | J Transl Med | 2026 | https://conductscience.org/library/papers/42760581 | PubMed |
| 42128668 | Cross-species transcriptomic integration reveals a MIRO1-mediated macrophage-T cell axis in glioma. | Life Sci Alliance | 2026 | https://conductscience.org/library/papers/42128668 | PubMed |
| 41930181 | Roles of ADP-Ribosyltransferases in Cancer. | Oncol Res | 2026 | https://conductscience.org/library/papers/41930181 | PubMed |
| 41463260 | Targeting MARylation and DePARylation in Cancer Therapy: New Promising Therapeutic Opportunities. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41463260 | PubMed |
| 41059489 | The Role of Immune Checkpoint Inhibitors in Cancer Therapy: Mechanism and Therapeutic Advances. | MedComm (2020) | 2025 | https://conductscience.org/library/papers/41059489 | PubMed |
| 40904702 | PARP (Poly ADP-ribose Polymerase) Family in Health and Disease. | MedComm (2020) | 2025 | https://conductscience.org/library/papers/40904702 | PubMed |
| 40741921 | Mono-ADP-ribosylating PARP enzymes in cellular signaling and disease. | J Cell Sci | 2025 | https://conductscience.org/library/papers/40741921 | PubMed |
| 40341026 | Development and optimization of Eva1 (MPZL2) targeting chimeric antigen receptor T cells. | J Immunother Cancer | 2025 | https://conductscience.org/library/papers/40341026 | PubMed |
| 40297580 | Immunocytes in the tumor microenvironment: recent updates and interconnections. | Front Immunol | 2025 | https://conductscience.org/library/papers/40297580 | PubMed |
| 40046061 | Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond. | Front Immunol | 2025 | https://conductscience.org/library/papers/40046061 | PubMed |
| 40017131 | Tumor‑associated neutrophils: Critical regulators in cancer progression and therapeutic resistance (Review). | Int J Oncol | 2025 | https://conductscience.org/library/papers/40017131 | PubMed |
| 39949782 | Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer. | Front Immunol | 2025 | https://conductscience.org/library/papers/39949782 | PubMed |
| 39189367 | PARP enzymes and mono-ADP-ribosylation: advancing the connection from interferon-signalling to cancer biology. | Expert Rev Mol Med | 2024 | https://conductscience.org/library/papers/39189367 | PubMed |
| 39167664 | Modified C-type natriuretic peptide normalizes tumor vasculature, reinvigorates antitumor immunity, and improves solid tumor therapies. | Sci Transl Med | 2024 | https://conductscience.org/library/papers/39167664 | PubMed |
| 39066732 | Pathological and physiological roles of ADP-ribosylation: established functions and new insights. | Biol Chem | 2024 | https://conductscience.org/library/papers/39066732 | PubMed |
| 39062190 | Expanding the Perspective on PARP1 and Its Inhibitors in Cancer Therapy: From DNA Damage Repair to Immunomodulation. | Biomedicines | 2024 | https://conductscience.org/library/papers/39062190 | PubMed |
| 39019005 | PARP11 inhibition inactivates tumor-infiltrating regulatory T cells and improves the efficacy of immunotherapies. | Cell Rep Med | 2024 | https://conductscience.org/library/papers/39019005 | PubMed |
| 38754421 | ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity. | Cell | 2024 | https://conductscience.org/library/papers/38754421 | PubMed |
| 38402224 | The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment. | Nat Commun | 2024 | https://conductscience.org/library/papers/38402224 | PubMed |
Genes16
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35637402
GET https://conductscience.org/api/papers/v1/35637402/authors?page=2